Clinical Implications and Treatment Strategies for ESR1 Fusions in Hormone Receptor-Positive Metastatic Breast Cancer: A Case Series

In hormone receptor-positive metastatic breast cancer (HR+ MBC), endocrine resistance is commonly due to genetic alterations of ESR1, the gene encoding estrogen receptor alpha (ERα). While ESR1 point mutations (ESR1-MUT) cause acquired resistance to aromatase inhibition (AI) through constitutive act...

Descripción completa

Detalles Bibliográficos
Autores principales: Brett, Jamie O, Ritterhouse, Lauren L, Newman, Erik T, Irwin, Kelly E, Dawson, Megan, Ryan, Lianne Y, Spring, Laura M, Rivera, Miguel N, Lennerz, Jochen K, Dias-Santagata, Dora, Ellisen, Leif W, Bardia, Aditya, Wander, Seth A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Precision Medicine Clinic: Molecular Tumor Board
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9907034/
https://www.ncbi.nlm.nih.gov/pubmed/36493359
http://dx.doi.org/10.1093/oncolo/oyac248

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9907034/
https://www.ncbi.nlm.nih.gov/pubmed/36493359
http://dx.doi.org/10.1093/oncolo/oyac248

Ejemplares similares